Biotech Stock Sunshine Biopharma Inc. (NASDAQ:SBFM) Makes NASDAQ Top Gainer List on News
April 2, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Sunshine Biopharma Inc. (NASDAQ:SBFM) a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals.
Biopharma makes the NASDAQ top percentage gainers list today on news, currently trading at $2.9008,, up 0.8108.gaining 38.7943% on volume of over 51 Million shares.
Biopharma today announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma.
Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.
We have optimized the expression level of our full-length mRNA (K1.1c) as well as a smaller, truncated version (K1.1d) in HCC tumors in mice. Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a dose-dependent manner by systemic administration. Under repeated dosing, the full-length K1.1c was found to reduce growth of three different types of human HCC tumors in mice with good tolerability. Proof-of-concept study of the truncated version K1.1d was conducted to assess its anti-tumor activity in HCC models in mice. A preliminary study suggested the truncated form of K1.1c could be highly expressed in engrafted tumors and had significant anti-tumor activity in mouse HCC models in a dose-dependent manner.
We are currently conducting additional animal studies to delineate optimum dosing of our truncated version (K1.1d) in different HCC model in mice to compare its dose-response and therapeutic window with those of the full-length (K1.1c). The smaller-sized mRNA of the truncated version offers the advantage of better efficacy at lower doses.
"We are pushing the frontier of mRNA therapy for cancer with our novel mRNA-LNP formulation," said Dr. Steve Slilaty, CEO of the Company. "Delivering mRNA via Lipid Nanoparticles (mRNA-LNP) is a new, revolutionary way to treat cancer. The performance of our K1.1-mRNA-LNP to date is simply remarkable, as we look ahead to the opportunity of delivering new life-saving treatments for cancer patients around the world."
Full news
https://finance.yahoo.com/news/sunshine-biopharma-announces-positive-results-120000007.html
Biotech stocks to watch:
Research more Biotech and medical technology stocks with Investorideas.com free stock directory
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.
Disclaimer/Disclosure: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, IR, PR and social media, podcast sponsorship and ticker tag content creation services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about digital advertising and guest posts/sponsored posts
https://www.investorideas.com/Advertise/
Follow us on X @investorideas @stocknewsbites
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Sign up for free stock news alerts at Investorideas.com
Contact Investorideas.com
800 665 0411
